ten23 health AG, headquartered in Switzerland (CH), is a pioneering company in the biopharmaceutical industry, specialising in the development of innovative drug delivery systems. Founded in 2020, ten23 health has quickly established itself as a leader in the field, focusing on the creation of unique formulations that enhance the efficacy and safety of therapeutic agents. With a strong operational presence across Europe, ten23 health AG offers a range of core services, including formulation development, analytical services, and regulatory support. Their commitment to advancing drug delivery technologies sets them apart, enabling clients to navigate complex challenges in the pharmaceutical landscape. Recognised for their expertise and innovative solutions, ten23 health continues to make significant strides in improving patient outcomes and solidifying their market position.
How does ten23 health AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
ten23 health AG's score of 59 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, ten23 health AG reported total carbon emissions of approximately 13,044,500 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 99% of the total. Specifically, Scope 1 emissions were 700 kg CO2e, and Scope 2 emissions were approximately 86,300 kg CO2e (market-based). The previous year, 2023, saw total emissions of about 15,423,300 kg CO2e, indicating a reduction in overall emissions. The company has set ambitious climate commitments, aiming to reduce its total emissions (Scopes 1, 2, and 3) by 90% by 2050, using 2023 as the baseline year. Additionally, ten23 health has committed to reducing its Scope 1 and Scope 2 emissions by 42% by 2030 from the same base year. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified as consistent with limiting global warming to 1.5°C. Ten23 health AG is also committed to achieving net-zero emissions by 2050, further solidifying its dedication to climate action. The company’s emissions data and reduction targets are not cascaded from any parent organization, indicating that these figures and commitments are independently reported.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | 000 | 000 | 000 |
| Scope 2 | 115,600 | 000,000 | 000,000 | 00,000 |
| Scope 3 | 282,900 | 0,000,000 | 00,000,000 | 00,000,000 |
ten23 health AG's Scope 3 emissions, which decreased by 15% last year and increased significantly since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Capital Goods" being the largest emissions source at 82% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ten23 health AG has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about ten23 health AG's sustainability data and climate commitments